Advanced Oncotherapy draws third tranche of Bracknor financing

Advanced Oncotherapy has drawn net proceeds of £1.235m in the third tranche of its Bracknor financing.

The company is a developer of next-generation proton therapy systems for cancer treatment.

In previous statements, Advanced Oncotherapy said proceeds from the Bracknor financing would continue to be allocated to its projects and for general working capital purposes.

At 14:18 BST, shares in Advanced Oncotherapy were down 4.49% at 21.25p each.